Bumetanide

• Mechanism of Action
• Inhibits the sodium-potassium-chloride cotransporters in the thick ascending limb of the loop of Henle, normally responsible for 25% of tubular sodium reabsorption. Inhibition results in increased excretion of sodium and, with it, water.

Clinical Use

• • Indications
  • Peripheral oedema – due to congestive cardiac failure / renal failure / nephrotic syndrome / cirrhosis
  • Acute pulmonary oedema
  • Symptomatic ascites (second line treatment)
• • Adverse Effects
  • Hypokalaemia
  • Hyponatraemia
  • Dehydration / hypovolaemia
  • Hyperuricaemia
  • Muscle cramps
  • Headache
  • Hepatic encephalopathy in patients with liver disease